Schroeckenfuchs assumed his current role in 2022, having joined Novartis in 2001. In June 2024, the company signed an MoU with Abu Dhabi’s Department of Health to advance clinical genomics research and explore radioligand therapy for cancer patients. Schroeckenfuchs is also an executive member of the MEA PhRMA Group, and a member of the Academic Marketing Society, and the Pharma Marketing Club Austria.